Cognito Therapeutics Announces Presentation of New CSF Proteomic and EEG Biomarker Data for Spectris™ in Alzheimer’s Disease at CTAD 2025 Cognito Therapeutics, a clinical-stage medical device company ...

Brain-derived extracellular vesicle (EV) biomarkers represent a promising frontier for liquid biopsy development targeting the nervous system. They offer strong potential for enabling minimally ...

Neurodegenerative diseases present some of the greatest challenges in medicine due to their complexity, heterogeneity, and the limited availability of reliable biomarkers and treatments. Join us for ...

Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration.

OTTAWA, Ontario — Looking for Alzheimer’s disease (AD) biomarkers in plasma instead of cerebrospinal fluid (CSF) is a simpler form of screening individuals for AD pathology and could result in earlier ...